Skip to Main Content
Contribute Try STAT+ Today

By disrupting the clinical trials process, the Covid-19 pandemic has served as a tipping point to advance decentralized clinical trials (DCTs) and other innovations in managing these essential studies.

To date, but primarily during the pandemic, most of the decentralized-related innovation has centered around infrastructure and process, mainly addressing the patient burdens and geographic barriers related to time, travel, and logistics. There’s been far less innovation on another key part of trial management: patient recruitment and retention, linchpins of clinical research.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment